Money · Lobbying reports · 119th Congress
H.R. 946
29 saved lobbying reports name H.R. 946.
29 reports
Confirmed from the official recordSenate Office of Public Records cannot vouch for the data or analyses derived from these data after the data have been retrieved from LDA.gov.
Lobbying Disclosure Act reports, LDA.gov. This copy was read October 7, 2026 at 6:29 PM Eastern.
Reports that name this bill
The amount is what the report gives for the whole quarter: everything the registrant did for that client, all issues together. A linked name opens that organization’s page on this site.
| Registrant | Client | Amount for the whole quarter | Quarter | Report |
|---|---|---|---|---|
| LMH STRATEGIC SOLUTIONS | ALKERMES, INC. | $60,000.00reported as income | April to June 2026 | Open the report |
| LMH STRATEGIC SOLUTIONS | ALNYLAM PHARMACEUTICALS, INC. | $50,000.00reported as income | April to June 2026 | Open the report |
| LMH STRATEGIC SOLUTIONS | IONIS PHARMACEUTICALS, INC. | $30,000.00reported as income | April to June 2026 | Open the report |
| LUNDBECK LLC | LUNDBECK LLC | $180,000.00reported as expenses | April to June 2026 | Open the report |
| GSK (FKA GLAXOSMITHKLINE INC.) | GSK (FKA GLAXOSMITHKLINE INC.) | $890,000.00reported as expenses | April to June 2026 | Open the report |
| TIBER CREEK GROUP | ALNYLAM PHARMACEUTICALS, INC. | $60,000.00reported as income | April to June 2026 | Open the report |
| DAIICHI SANKYO, INC. | DAIICHI SANKYO INC | $380,000.00reported as expenses | April to June 2026 | Open the report |
| TRAVERE THERAPEUTICS | TRAVERE THERAPEUTICS | $140,000.00reported as expenses | April to June 2026 | Open the report |
| PTC THERAPEUTICS, INC. | PTC THERAPEUTICS, INC. | $170,000.00reported as expenses | April to June 2026 | Open the report |
| ACADIA PHARMACEUTICALS | ACADIA PHARMACEUTICALS | $700,000.00reported as expenses | April to June 2026 | Open the report |
| NEUROCRINE BIOSCIENCES, INC | NEUROCRINE BIOSCIENCES, INC | $940,000.00reported as expenses | April to June 2026 | Open the report |
| CHRONIC CARE POLICY ALLIANCE | CHRONIC CARE POLICY ALLIANCE | The report gives no amount | April to June 2026 | Open the report |
| ASTRAZENECA PHARMACEUTICALS LP | ASTRAZENECA PHARMACEUTICALS LP | $1,680,000.00reported as expenses | April to June 2026 | Open the report |
| TAKEDA PHARMACEUTICALS AMERICA, INC. | TAKEDA PHARMACEUTICALS AMERICA INC | $610,000.00reported as expenses | April to June 2026 | Open the report |
| NOVARTIS | NOVARTIS | $1,410,000.00reported as expenses | April to June 2026 | Open the report |
| INCYTE CORPORATION | INCYTE CORPORATION | $750,000.00reported as expenses | April to June 2026 | Open the report |
| AVENUE SOLUTIONS | JAZZ PHARMACEUTICALS, INC. | $50,000.00reported as income | April to June 2026 | Open the report |
| BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC | BOEHRINGER INGELHEIM USA CORPORATION | $710,000.00reported as expenses | April to June 2026 | Open the report |
| W STRATEGIES, LLC | ASTRAZENECA PHARMACEUTICALS LP | $80,000.00reported as income | April to June 2026 | Open the report |
| W STRATEGIES, LLC | CALIFORNIA LIFE SCIENCES | $40,000.00reported as income | April to June 2026 | Open the report |
| W STRATEGIES, LLC | INCYTE CORPORATION | $60,000.00reported as income | April to June 2026 | Open the report |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | $7,360,000.00reported as expenses | April to June 2026 | Open the report |
| JOHNSON & JOHNSON SERVICES, INC. | JOHNSON & JOHNSON SERVICES INC | $1,440,000.00reported as expenses | April to June 2026 | Open the report |
| JAZZ PHARMACEUTICALS, INC. | JAZZ PHARMACEUTICALS, INC. | $490,000.00reported as expenses | April to June 2026 | Open the report |
| TODD STRATEGY GROUP | ALNYLAM PHARMACEUTICALS, INC. | $60,000.00reported as income | April to June 2026 | Open the report |
| AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP) | AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | $3,010,000.00reported as expenses | April to June 2026 | Open the report |
| BIOGEN | BIOGEN | $1,060,000.00reported as expenses | April to June 2026 | Open the report |
| ALSTON & BIRD LLP | TRAVERE THERAPEUTICS | $70,000.00reported as income | April to June 2026 | Open the report |
| EMD SERONO, INC. | EMD SERONO INC | $700,000.00reported as expenses | April to June 2026 | Open the report |